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1 TREATMENT
Extended version of the Lee Silverman Voice Treatment (LSVT)
results in changes to vocal sound pressure level comparable
5 to those resulting from traditional LSVT in a group of
12 participants1
Megan J. McAuliffe (Commentary author), Department of Communication Disorders, University of Canterbury,
New Zealand
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Q (1) Does an extended version of the Lee Silverman Voice Treatment (LSVT), completed over a 2-monthperiod, result in significant increases in vocal sound pressure level in patients with Parkinson’s
disease? (2) If so, are these increases comparable to those in a previous LSVT study? (3) Does this
extended version of LSVT result in functional improvement to communication?
15
METHODS
Design: A pre-test–post-test design was completed
in order to determine if an extended Lee Silverman
Voice Treatment (LSVT) program (LSVT-X) results in
significant increases to vocal sound pressure level
(SPL) and significant functional improvement in
communication. LSVT-X results for vocal SPL and a
perceptual rating of speech were then compared with
the results of a previous study examining traditional
LSVT (Ramig, Sapir, Fox, & Countryman, 2001), to
determine whether any changes observed were
comparable to previous LSVT findings.
Allocation: As the study involved a single LSVT-X
group, allocation was not required. However, decep-
tion was employed, with the authors informing
participants that they would be allocated to either a
1-month or 2-month intervention group. The authors
stated that this was undertaken to ensure participant
motivation levels were consistent with previous
studies.
Blinding: Unblinded. As no specific information was
provided, it was assumed that blinding was not
conducted. The authors stated that data collection
was not conducted by the treating therapist; however,
it would seem that both the treating therapist and
assessor were aware of the purpose of the study.
In addition, no information was provided regarding
blinding of those who conducted the perceptual
ratings; therefore, it is assumed that they too were
aware of the study purpose.
Study length: The study was conducted over a
6-month period.
Setting: The setting was not specified. It was
probably conducted at the National Center for
Voice and Speech, in Denver, Colorado, USA.
Participants: 12 individuals (9 male, 3 female) with
idiopathic Parkinson’s disease were included in the
study. All participants exhibited speech characteristics
typical of Parkinson’s disease, were on stable medical
regimens during the study, lived independently,
and exhibited cognitive abilities adequate to complete
all assessment and treatment tasks. Mean age of the
group was 67.210 years, with an average disease
duration of 4.83.1 years.
Intervention: Participants completed an extended
version of the traditional LSVT program. This was
named LSVT-X for the purposes of the study.
Traditional LSVT is conducted in 1-h treatment
sessions, four times per week for four consecutive
weeks (a total of 16 1-h sessions over a 4-week
period). For full details of LSVT treatment tasks
and treatment hierarchy see Ramig, Countryman,
O’Brien, Hoehn, and Thompson (1996). In contrast
to traditional LSVT, LSVT-X comprised two 1-h
sessions per week for eight consecutive weeks.
Treatment tasks followed the same hierarchy as
traditional LSVT treatment; however, they were
spread over a 2-week, rather than 1-week, period.
Homework tasks were conducted as per traditional
LSVT, that is, 5–10 min on treatment days and
20–30 min on non-treatment days. Therefore, given
the extended duration of LSVT-X, participants in this
study undertook significantly more home practice
than those who have previously completed traditional
LSVT. Specific measures of treatment fidelity were
not included. It was noted that the treating therapist
was a certified LSVT practitioner.
Outcomes: Objective outcome measures included
vocal SPL in sustained phonation, reading, picture
description and conversational speech. Functional
improvement was assessed using the Voice Handicap
Index (VHI) (Jacobson et al., 1997), a questionnaire
that examines psychosocial function related to voice.
Speech outcomes were rated on a visual analogue
scale. Specifically, four speech pathology graduate
students listened to sentence pairs (one sentence
collected pre-treatment, the other post-treatment,
taken from the Rainbow Passage) and rated whether
the second sample sounded ‘better’ or ‘worse’ than
the previous sample. Anchor points were –50 (much
worse) and þ50 (much better). A rating of 0 indicated
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MAIN RESULTS
LSVT-X resulted in significant improvements to vocal
SPL across all conditions (sustained phonation,
reading, picture description, and conversation)
20 immediately following treatment. Significant
increases in vocal SLP were also observed from pre-
treatment to 6-month follow-up for sustained
phonation, reading, and picture description.
Although vocal SPL in conversation increased
25 between the pre-treatment and 6-month follow-
ups, this difference was not statistically significant.
Across all conditions, there were no significant
decreases in vocal SPL between the post-treatment
and 6-month follow-ups.
30 When the results of LSVT-X group were compared
with the group results of those who received
traditional LSVT in a previous study (Ramig et al.,
2001), the groups exhibited similar pre-treatment
vocal SPL across all conditions. In addition, the
35 groups exhibited similar vocal SPL levels at the
post-treatment and 6-month follow-ups. Only
one significant difference was observed, with vocal
SPL for the picture description task significantly
increased post-treatment in the LSVT-X group.
40 As expected, the LSVT-X group exhibited signifi-
cantly higher vocal SPL at post-treatment and
6-month follow-ups when compared with the
group from Ramig et al. (2001), which received no
treatment.
45 Functionally, there was no significant change in
VHI scores for the LSVT-X group post-treatment.
When individual scores were examined, 33% of
participants reported significant improvements to
voice handicap following treatment. None of the
50 participants exhibited significant worsening imme-
diately after or at 6 months after treatment.
The perceptual speech ratings of the LSVT-X group
in the current study and traditional-LSVT and
no-treatment groups in Ramig et al.’s study (2001)
55 were compared. The LSVT-X and LSVT groups’
speech was rated significantly ‘better’ immediately
post-treatment, compared with the group who did
not receive treatment.
AUTHORS’ CONCLUSIONS
60The group of 12 participants who received LSVT-X
exhibited significantly increased vocal SPL following
treatment. In addition, their speech was perceived as
‘better’ immediately post-treatment. These findings
appeared consistent with the results of traditional
65LSVT collected from a previous study (Ramig et al.,
2001). Overall, self-ratings on the VHI suggested
that participants were less negatively affected by
their voices following LSVT-X.
that both samples sounded the same. Vocal SPL
measures and the VHI were followed up immediately
post-treatment at 6 months post-treatment. The
perceptual speech rating was followed up immedi-
ately post-treatment only. Reliability data were
reported for the perceptual ratings only.
Attrition: Of the 15 participants initially recruited,
12 completed the study. One person withdrew due to
complications from an unrelated medical condition.
Results from two further participants were removed
from the data set as they were later diagnosed with
multiple systems atrophy and progressive supra-
nuclear palsy, respectively.
Commentary
G
iven service delivery and funding constraints, this
preliminary study provides a welcome addition to the
literature in the area of speech intervention for
individuals with Parkinson’s disease. The findings of this
study are promising. However, as acknowledged by the
authors, further research including larger participant numbers,
and prospective control groups (e.g. traditional LSVT and no
treatment) is required to determine the efficacy of LSVT-X as
a model of service delivery for people with Parkinson’s disease.
One particular limitation of this study was the lack of blinding.
The article stated that ‘‘no treating therapist collected data,
and therapists were kept out of sight during data collection to
avoid acting as external cues or biasing data collection’’
(Spielman, Ramig, Mahler, Halpern, & Gavin, 2007, p. 98).
It is therefore assumed that those assessing and treating
participants were aware of the study purposes. As stated in the
text, ‘‘participants were never cued for vocal loudness during
data collection sessions’’ (Spielman et al., 2007, p. 98).
However, inadvertent cueing can introduce unavoidable bias
into the study results. Future LSVT-X studies would be
strengthened by the use of blinding, particularly blinding
of assessors. In addition, the inclusion of specific measures
of treatment fidelity would further strengthen the study design.
The perceptual assessment of speech could also be
strengthened for future studies. Firstly, it is unknown why the
authors chose to undertake speech analysis for the pre-
treatment and immediately post-treatment conditions only. The
required stimuli were collected at 6 months in both the present
study and Ramig et al. (2001). It would have been of interest to
readers to know whether speech improvements were main-
tained 6 months following treatment. Secondly, the number of
listeners included (four) was quite small for a perceptual
speech analysis. Thirdly, it is assumed that listeners were not
blinded to the study purpose, which introduces the possibility of
bias. Given the small number of listeners, lack of follow-up,
and potential for bias, only limited conclusions can be drawn
from the speech analysis.
Regarding the VHI results, overall, the average self-rating
score dropped from 44 to 30 immediately post-treatment, and
rose to 32 at 6-month follow up. The drop immediately post-
treatment was interpreted as a drop from intermediate to mild
voice handicap. This change was not statistically significant,
which might be related to the small number of participant.
authors noted that four participants exhibited a significant
improvement in voice handicap immediately post-treatment.
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This was maintained by three participants at 6 months post-
treatment. Without seeing the full data set, it is difficult to
comment; however, the authors conclusions that ‘‘self-ratings
using the VHI also suggest that, on the whole, participants
who received LSVT-X were less negatively affected by their
voices following treatment and did not perceive decline over
a 6-month period’’ (Spielman et al., 2007, p. 103) seems a
slightly generous interpretation of the current findings.
In summary, this study provides some evidence that LSVT-X
results in similar improvements to speech and voice as does
traditional LSVT. However, the comparisons to traditional LSVT
are made across studies, rather than within this study, and thus
must be viewed as preliminary. Additionally, the results of
the study should be interpreted with caution given the small
number of participants and lack of control groups. However,
the potential for modified treatment schedules is a promising
line of enquiry, and future research will be of great interest
to clinicians and researchers in the area of motor–speech
disorders.
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